Navigation Links
Derma Sciences Announces Commercial Launch of XTRASORB(TM)
Date:10/21/2008

Novel polymer-based super-absorbent dressing will be first of its kind in

US and Canada

PRINCETON, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a company specializing in advanced wound care, today announced the commercial launch of its newest product -- XTRASORB(TM) Super Absorbent Dressing. The novel dressing features a polymer-based core that could help change the way clinicians manage heavily exuding wounds, currently a significant issue in wound care. The dressing will be launched at next week's Clinical Symposium on Advances in Skin & Wound Care in Las Vegas.

Commenting on the launch, CEO Ed Quilty stated, "This is something we have been excited about for quite a while. Foam dressings, for highly exuding wounds, is the single largest category of moist wound dressings, with over $300 million in global sales. Still, even the best dressings in this category have limitations. Clinicians still want dressings to hold more fluid to reduce the number of time-consuming and costly dressing changes. Additionally, the fluid that a foam dressing does absorb is at a high risk of being pushed back onto the wound bed, potentially causing serious complications to the wound. For these reasons, our market research shows that clinicians will love the fact that XTRASORB can absorb roughly 50% more than even the most absorbent foam dressing, and that the polymer-based super-absorbent core forms a gel which locks all the wound fluid inside the dressing and away from the wound. This has multiple benefits, including reducing the risk of wound breakdown due to excessive moisture, as well as keeping harmful bacteria often found in wound fluid away from the wound."

Quilty continued, "Based on our research and feedback from customers, we are extremely confident that we will have another successful product launch. We launched MEDIHONEY(R) Dressings last year at the Clinical Symposium, and we have done very well with that product. Our expectations for XTRASORB are very high, and we look forward to it being a significant contributor to our overall growth moving forward. This is yet another step in the course we've charted out over the past several years -- using the cash flow from our $50+ million revenue baseline business to fund the development of novel higher margin advanced wound care products, and then to launch and support them with marketing and our growing sales organization. This is what is going to drive our topline growth and profitability."

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com

(609) 514-4744 Brian Kennedy (media)

brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
2. Age Spots Are No Match for Cosmetic Dermatology Treatments
3. Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U.S. Open
4. Watson Announces Limited Recall of Fentanyl Transdermal System
5. Derma Sciences Conference Call Advisory
6. American Academy of Dermatology: Dermatologists Warn Ceramic Flat Irons Could Damage Hair and Lead to Hair Breakage
7. American Academy of Dermatology: Acne and Rosacea Got You Seeing Red? Patients with Skin of Color Advised to Seek Proper Diagnosis, Treatment to Prevent Common Side Effects
8. Galderma announces approval for Differin gel 0.1 percent in Japan
9. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
10. 4th Annual Dermatology Nurses Association Summer Meeting to Arrive in Windy City
11. Derma Sciences Launches Two New MEDIHONEY(TM) Formulations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology: